Total 2014 Compensation: $25.82 million
Heather Bresch has taken a bit of a back seat in the media lately to Mylan Chairman Robert Coury, the company's outspoken mouthpiece, as it works to fight off an unwanted takeover by Teva Pharmaceutical Industries ($TEVA). Coury has been firing off regular missives to Teva chief Erez Vigodman, using all sorts of colorful language to discredit the potential deal.
But Bresch hasn't exactly been silent. She's as much an advocate as Coury for Mylan's ($MYL) preferred transaction: a takeout of Perrigo ($PRGO), the Ireland-based over-the-counter drugmaker that specializes in store brands. And it would be the latest in a series of deals for the CEO.
Most recently, Bresch led Mylan through the $5.3 billion buyout of a big chunk of Abbott Laboratories' ($ABT) remaining drug business, a deal that closed in late February. Along with 100 branded and generic meds, the stock-based transaction added Abbott's commercial infrastructure in a host of countries, putting its own meds--including its branded injection for anaphylactic shock, EpiPen--in line for sales growth.
That Abbott deal--which involved developed markets outside the U.S.--followed a series of expansion moves in emerging markets, including the purchase of India-based Agila Specialties, Strides Arcolab's injectable drug business. The company has teamed up with Gilead Sciences ($GILD) to roll out HIV drugs in India, launched a biosimilar version of Roche's ($RHHBY) blockbuster cancer drug Herceptin in partnership with India's Biocon, and snapped up a series of Indian plants and development facilities.
The Perrigo buyout would be Mylan's biggest deal ever, however, and Abbott recently gave the company its backing, pledging to vote its 15% stake in favor. So far, however, Perrigo isn't biting on Mylan's $33 billion-or-so offer, calling it much too low. And Teva isn't backing away from its quest to snap up its U.S.-based rival with its own $40 billion-plus bid.
Whether Bresch will even be eligible for next year's CEO-pay ranking, then, remains to be seen. But for now, she's firmly ensconced in the top 10 with her $25.8 million total. Options accounted for $14.4 million of that amount, with base salary and nonequity incentive pay of $1.18 million and $3.26 million. Bresch also collected $4.8 million worth of stock awards and $633,000 in other compensation. Her pension growth and deferred compensation of $1.55 million rounded out the total.
Special Reports: Pharma's top 10 M&A deals of 2014 - Mylan/Abbott Laboratories established products | 20 Highest-Paid Biopharma CEOs of 2012 - Heather Bresch - Mylan
Teva turns up the heat on Mylan, taking its stake past critical threshold
Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to go
To avoid becoming deal bait, Mylan CEO may have to make another big buy
Mylan beefs up outside the U.S. with $5.3B deal for Abbott drug business
Mylan to get Strides' vast sterile injectable capacity